Central hyperthermia in cases of traumatic brain injury (TBI) is often misdiagnosed or underdiagnosed due to inadequate data. The current diagnosis is one of exclusion. Existing treatment as per guidelines is symptomatic and supportive. Continuous fever after TBI may delay therapy, worsen functional outcome and prolong hospital stay. We discuss a case of a 33-year-old gentleman with TBI with recurring fever spikes during inpatient rehabilitation, non-responsive to antipyretics and antibiotics. A diagnosis of central hyperthermia was reached after eliminating other possible causes. Based on a prior case report, baclofen was tried successfully to manage central hyperthermia. In our patient, a complete cessation of fever was noted within 2 days of initiation of baclofen. To test the effect and minimise the possibility of coincidental dissipation of fever, baclofen was temporarily withdrawn. The corresponding decrease in temperatures and days of baclofen administration followed by recurrence with cessation, are depicted graphically. Once baclofen was resumed, he remained afebrile for the remainder of his inpatient period. This case brings to light the possible efficacy of low-dose baclofen in the management of fever of central origin. It also highlights the importance of considering the possibility of fever of central origin in the subacute stage after TBI. Standardisation of baclofen use with well-designed clinical trials is the proposed next step.